HSP70 inhibition limits FAK-dependent invasion and enhances the response to melanoma treatment with BRAF inhibitors

Cancer Research

Volumn 76, Issue 9, 2016, Pages 2720-2730

  Budina Kolomets, Anna ^a   Webster, Marie R ^a   Leu, Julia I Ju ^b   Jennis, Matthew ^a   Krepler, Clemens ^a   Guerrini, Anastasia ^a   Kossenkov, Andrew V ^a   Xu, Wei ^c   Karakousis, Giorgos ^b   Schuchter, Lynn ^c   Amaravadi, Ravi K ^c   Wu, Hong ^d   Yin, Xiangfan ^a   Liu, Qin ^a   Lu, Yiling ^e   Mills, Gordon B ^e   Xu, Xiaowei ^c   George, Donna L ^b   Weeraratna, Ashani T ^a   Murphy, Maureen E ^a  

^a WISTAR INSTITUTE   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

^d FOX CHASE CANCER CENTER   (United States)

^e UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; HEAT SHOCK PROTEIN 70; TRIPHENYL(PHENYLETHYNYL)PHOSPHONIUM BROMIDE; UNCLASSIFIED DRUG; VEMURAFENIB; B RAF KINASE; BRAF PROTEIN, HUMAN; FOCAL ADHESION KINASE 1; INDOLE DERIVATIVE; PTK2 PROTEIN, HUMAN; SULFONAMIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL VIABILITY; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFECT; DRUG RESPONSE; FEMALE; HUMAN; HUMAN CELL; INHIBITION KINETICS; LUNG METASTASIS; MELANOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR INVASION; TUMOR VOLUME; ANIMAL; ANTAGONISTS AND INHIBITORS; C57BL MOUSE; CELL PROLIFERATION; DRUG EFFECTS; DRUG RESISTANCE; FLUORESCENT ANTIBODY TECHNIQUE; GENE SILENCING; IMMUNOHISTOCHEMISTRY; IMMUNOPRECIPITATION; METABOLISM; PATHOLOGY; TISSUE MICROARRAY; WESTERN BLOTTING;

ANIMALS; ANTINEOPLASTIC AGENTS; BLOTTING, WESTERN; CELL PROLIFERATION; DRUG RESISTANCE, NEOPLASM; FLUORESCENT ANTIBODY TECHNIQUE; FOCAL ADHESION KINASE 1; GENE KNOCKDOWN TECHNIQUES; HSP70 HEAT-SHOCK PROTEINS; HUMANS; IMMUNOHISTOCHEMISTRY; IMMUNOPRECIPITATION; INDOLES; MELANOMA; MICE; MICE, INBRED C57BL; NEOPLASM INVASIVENESS; PROTO-ONCOGENE PROTEINS B-RAF; SULFONAMIDES; TISSUE ARRAY ANALYSIS;

EID: 84969651143     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-15-2137     Document Type: Article

References (41)

1. Fedorenko IV, Gibney GT, Sondak VK, Smalley KS. Beyond BRAF: Where next for melanoma therapy? Br J Cancer 2015;112:217-26.
2. Murphy ME. The HSP70 family and cancer. Carcinogenesis 2013;34:1181-8.
3. Daugaard M, Rohde M, Jaattela M. The heat shock protein 70 family: Highly homologous proteins with overlapping and distinct functions. FEBS Lett 2007;581:3702-10.
4. Hunt CR, Dix DJ, Sharma GG, Pandita RK, Gupta A, Funk M, et al. Genomic instability and enhanced radiosensitivity in Hsp70. 1-and Hsp70. 3-defi-cient mice. Mol Cell Biol 2004;24:899-911.
5. Ciocca DR, Calderwood SK. Heat shock proteins in cancer: Diagnostic, prognostic, predictive, and treatment implications. Cell Stress Chaperones 2005;10:86-103.
6. Leu JI, Pimkina J, Frank A, Murphy ME, George DL. A small molecule inhibitor of inducible heat shock protein 70. Mol Cell 2009;36:15-27.
7. Balaburski GM, Leu JI, Beeharry N, Hayik S, Andrake MD, Zhang G, et al. A modified HSP70 inhibitor shows broad activity as an anticancer agent. Mol Cancer Res 2013;11:219-29.
8. Leu JI, Pimkina J, Pandey P, Murphy ME, George DL. HSP70 inhibition by the small-molecule 2-phenylethynesulfonamide impairs protein clearance pathways in tumor cells. Mol Cancer Res 2011;9:936-47.
9. Leu JI, Zhang P, Murphy ME, Marmorstein R, George DL. Structural basis for the inhibition of HSP70 and DnaK chaperones by small-molecule targeting of a C-terminal allosteric pocket. ACS Chem Biol 2014;9: 2508-16.
10. Budina-Kolomets A, Balaburski GM, Bondar A, Beeharry N, Yen T, Murphy ME. Comparison of the activity of three different HSP70 inhibitors on apoptosis, cell cycle arrest, autophagy inhibition, and HSP90 inhibition. Cancer Biol Ther 2014;15:194-9.
11. Milani V, Frankenberger B, Heinz O, Brandl A, Ruhland S, Issels RD, et al. Melanoma-associated antigen tyrosinase but not Melan-A/MART-1 expression and presentation dissociate during the heat shock response. Int Immunol 2005;17:257-68.
12. Frank AK, Leu JI, Zhou Y, Devarajan K, Nedelko T, Klein-Szanto A, et al. The codon 72 polymorphism of p53 regulates interaction with NF-{kappa}B and transactivation of genes involved in immunity and inflammation. Mol Cell Biol 2011;31:1201-13.
13. Chou TC, Talalay P. Quantitative analysis of dose-effect relationships: The combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 1984;22:27-55.
14. Robertson D, Savage K, Reis-Filho JS, Isacke CM. Multiple immunofluorescence labelling of formalin-fixed paraffin-embedded (FFPE) tissue. BMC Cell Biol 2008;9:13.
15. Xu XZ, Garcia MV, Li TY, Khor LY, Gajapathy RS, Spittle C, et al. Cytoskeleton alterations in melanoma: Aberrant expression of cortactin, an actin-binding adapter protein, correlates with melanocytic tumor progression. Mod Pathol 2010;23:187-96.
16. Kumar SM, Acs G, Fang D, Herlyn M, Elder DE, Xu X. Functional erythropoietin autocrine loop in melanoma. Am J Pathol 2005;166:823-30.
17. Li L, Fukunaga-Kalabis M, Herlyn M. The three-dimensional human skin reconstruct model: a tool to study normal skin and melanoma progression. J Vis Exp 2011.
18. Iadevaia S, Lu Y, Morales FC, Mills GB, Ram PT. Identification of optimal drug combinations targeting cellular networks: integrating phospho-proteomics and computational network analysis. Cancer Res 2010;70:6704-14.
19. Tibes R, Qiu Y, Lu Y, Hennessy B, Andreeff M, Mills GB, et al. Reverse phase protein array: Validation of a novel proteomic technology and utility for analysis of primary leukemia specimens and hematopoietic stem cells. Mol Cancer Ther 2006;5:2512-21.
20. Kannengiesser C, Spatz A, Michiels S, Eychene A, Dessen P, Lazar V, et al. Gene expression signature associated with BRAF mutations in human primary cutaneous melanomas. Mol Oncol 2008;1:425-30.
21. Parker KA, Glaysher S, Polak M, Gabriel FG, Johnson P, Knight LA, et al. The molecular basis of the chemosensitivity of metastatic cutaneous melanoma to chemotherapy. J Clin Pathol 2010;63:1012-20.
22. Ricaniadis N, Kataki A, Agnantis N, Androulakis G, Karakousis CP. Longterm prognostic significance of HSP-70, c-myc and HLA-DR expression in patients with malignant melanoma. Eur J Surg Oncol 2001;27:88-93.
23. Mizuno H, Kitada K, Nakai K, Sarai A. PrognoScan: a new database for metaanalysis of the prognostic value of genes. BMC Med Genomics 2009;2:18.
24. Dankort D, Curley DP, Cartlidge RA, Nelson B, Karnezis AN, Damsky WEJr., et al. Braf(V600E) cooperates with Pten loss to induce metastatic melanoma. Nat Genet 2009;41:544-52.
25. Tabchy A, Hennessy BT, Gonzalez-Angulo AM, Bernstam FM, Lu Y, Mills GB. Quantitative proteomic analysis in breast cancer. Drugs Today (Barc) 2011;47:169-82.
26. Smalley KS, Haass NK, Brafford PA, Lioni M, Flaherty KT, Herlyn M. Multiple signaling pathways must be targeted to overcome drug resistance in cell lines derived from melanoma metastases. Mol Cancer Ther 2006; 5:1136-44.
27. Ma XH, Piao SF, Dey S, McAfee Q, Karakousis G, Villanueva J, et al. Targeting ER stress-induced autophagy overcomes BRAF inhibitor resistance in melanoma. J Clin Invest 2014;124:1406-17.
28. O'Connell MP, Marchbank K, Webster MR, Valiga AA, Kaur A, Vultur A, et al. Hypoxia induces phenotypic plasticity and therapy resistance in melanoma via the tyrosine kinase receptors ROR1 and ROR2. Cancer Discov 2013;3:1378-93.
29. Shibata Y, Morimoto RI. How the nucleus copes with proteotoxic stress. Curr Biol 2014;24:R463-74.
30. Juhasz K, Lipp AM, Nimmervoll B, Sonnleitner A, Hesse J, Haselgruebler T, et al. The complex function of hsp70 in metastatic cancer. Cancers (Basel) 2013;6:42-66.
31. Powers MV, Clarke PA, Workman P. Dual targeting of HSC70 and HSP72 inhibits HSP90 function and induces tumor-specific apoptosis. Cancer Cell 2008;14:250-62.
32. Rohde M, Daugaard M, Jensen MH, Helin K, Nylandsted J, Jaattela M. Members of the heat-shock protein 70 family promote cancer cell growth by distinct mechanisms. Genes Dev 2005;19:570-82.
33. Yaglom JA, Gabai VL, Sherman MY. High levels of heat shock protein Hsp72 in cancer cells suppress default senescence pathways. Cancer Res 2007;67:2373-81.
34. Gabai VL, Yaglom JA, Waldman T, Sherman MY. Heat shock protein Hsp72 controls oncogene-induced senescence pathways in cancer cells. Mol Cell Biol 2009;29:559-69.
35. Rerole AL, Gobbo J, De Thonel A, Schmitt E, Pais de Barros JP, Hammann A, et al. Peptides and aptamers targeting HSP70: a novel approach for anticancer chemotherapy. Cancer Res 2011;71:484-95.
36. Colvin TA, Gabai VL, Gong J, Calderwood SK, Li H, Gummuluru S, et al. Hsp70-Bag3 interactions regulate cancer-related signaling networks. Cancer Res 2014;74:4731-40.
37. Paraiso KH, Haarberg HE, Wood E, Rebecca VW, Chen YA, Xiang Y, et al. The HSP90 inhibitor XL888 overcomes BRAF inhibitor resistance mediated through diverse mechanisms. Clin Cancer Res 2012;18:2502-14.
38. Smyth T, Paraiso KH, Hearn K, Rodriguez-Lopez AM, Munck JM, Haarberg HE, et al. Inhibition of HSP90 by AT13387 delays the emergence of resistance to BRAF inhibitors and overcomes resistance to dual BRAF and MEK inhibition in melanoma models. Mol Cancer Ther 2014;13: 2793-804.
39. Ueno Y, Sakurai H, Tsunoda S, Choo MK, Matsuo M, Koizumi K, et al. Heregulin-induced activation of ErbB3 by EGFR tyrosine kinase activity promotes tumor growth and metastasis in melanoma cells. Int J Cancer 2008;123:340-7.
40. Raychaudhuri P, Park HJ. FoxM1: A master regulator of tumor metastasis. Cancer Res 2011;71:4329-33.
41. Spagnolo F, Ghiorzo P, Orgiano L, Pastorino L, Picasso V, Tornari E, et al. BRAF-mutant melanoma: treatment approaches, resistance mechanisms, and diagnostic strategies. Onco Targets Ther 2015;8:157-68.